Elanco (ELAN)
Health Care · Animal Health · NYSE
Elanco is a pure-play animal health leader focused on innovating treatments and wellness solutions for pets and livestock worldwide.
What Elanco does
Elanco is a global animal health company that develops, manufactures, and markets products for the prevention and treatment of disease in both pets and farm animals. Its portfolio includes a broad range of veterinary pharmaceuticals, vaccines, and animal health additives aimed at improving animal well-being and productivity. The company operates across global markets, focusing on both companion animal health and farm animal health segments.
Themes: animal health, companion animal wellness, livestock productivity, veterinary medicine
Fundamentals
- Price$23.97 as of 2026-08-21 close
- Market cap$12.0B as of 2026-08-21
- 1-year return+37.0% 2025-08-21 close $17.49 → 2026-08-21 close $23.97
- P/En/a negative earnings
- Net margin-4.0% as of 2026-08-24
- Gross margin+55.4% as of 2026-08-24
- ROE-3.0% as of 2026-08-24
- Debt / equity0.59 as of 2026-08-24
- Revenue growth (YoY)+11.9% as of 2026-08-24
- Revenue CAGR (3y)+2.2% SEC XBRL
- Beta1.72 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ELAN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ELAN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
46.7 #1007 of 1,704 scored · #175 of 240 in Health Care
Catalysts 62nd: open-market insider buys in 90 days 40, the analyst consensus rating is unchanged since the prior reading; momentum 56th: MACD momentum is positive; weakest is volume and participation 23rd: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Elanco looks technically
Elanco (ELAN) is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 286 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.54 | $24.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.58 | $23.58 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 286 trading days ago — a "golden cross", a bullish long-term signal | 286 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.6% above | +1.6% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 48.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.32 to $27.98) — its "stochastic" reading is 40 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 39.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.98 | $27.98 |
|---|---|---|
| From the 52-week high | it is 14.3% below its 52-week high (its highest price of the past year) | -14.3% |
| Above the 52-week low | it is 40.1% above its 52-week low (its lowest price of the past year) | +40.1% |
| Below the 52-week high | it is 14.3% below its highest point of the past year | 14.3% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $37.61 (set on 2018-09-27) | $37.61 |
| Given back of the 52-week move | over the past year its closes ranged ($17.35 to $26.84), and it has given back roughly a third of its rise from last year’s low — 30% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.67 to $20.98. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.2% |
| From the all-time high | it is 36.3% below its all-time high | -36.3% |
| Nearest price level | it is trading 1.1% above a support level at $23.72 — a price it turned at four times since 2025-11-26, most recently on 2026-07-08. Since 2024-08-21 it has 18 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $7.88 (set on 2023-05-31) | $7.88 |
| Above the all-time low | it is 204.2% above its all-time low | +204.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months) | 84th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.03 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.34 and $27.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.34 – $24.33 – $27.32 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges above its 200-day average price (1.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.5% |
|---|---|---|
| Open gap | it gapped 3.3% below the previous close 11 sessions ago and has not traded back through the level it left behind at 26.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.3% |
| Gap filled | a 3.2% gap up opened on 2026-08-11 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 7 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.3 percentage points (the stock lost 5.9% while the market gained 2.3%) | -8.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.3 percentage points (the stock gained 12.4% while the market gained 3.1%) | +9.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.1 percentage points (the stock lost 4.0% while the market gained 11.1%) | -15.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.6 percentage points (the stock gained 37.0% while the market gained 20.5%) | +16.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $23.94 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +0.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $23.32 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +2.8% |
Price levels it has turned at before
ELAN last closed at $23.97 on 2026-08-21. Since 2024-08-21 it has turned at 18 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.72 | Support | 1.1% below the last close | turned there four times · 2025-11-26 to 2026-07-08 |
| $24.50 | Resistance | 2.2% above the last close | turned there twice · 2026-04-15 to 2026-07-23 |
| $23.08 | Support | 3.7% below the last close | turned there twice · 2025-11-12 to 2026-06-23 |
| $25.18 | Resistance | 5.0% above the last close | turned there twice · 2026-01-22 to 2026-06-15 |
| $22.62 | Support | 5.6% below the last close | turned there three times · 2025-12-18 to 2026-06-11 |
| $25.62 | Resistance | 6.9% above the last close | turned there twice · 2026-03-17 to 2026-03-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.41 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$31.21 range $26.00 – $34.00; median $31.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ELAN
- Consensus EPS estimate$0.2026 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High level of debt which restricts operating flexibility and increases interest rate sensitivity.","Dependence on R&D success and regulatory approvals for new product launches.","Intense competition from generic animal health products and evolving veterinary practices."]
What changed in the latest 10-Q
AI-assisted comparison of ELAN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added paragraph in Business Overview: 'We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve.'
- Added to Business Overview: 'Our purpose — making life better for animals makes life better — inspires us to Go Beyond for animals, our customers, our people, and society.'
- Added product: Befrena monoclonal antibody injection received USDA approval in December 2025 with anticipated Q2 2026 launch
- Added section 'Restructuring Activities' describing December 2025 Board authorization of 2025 Restructuring Plan affecting R&D facilities in Monheim Germany and Kansas City Kansas manufacturing facility, with $155 million Q4 2025 charges and expected $25-30 million 2026 charges
- Added detailed tariff information: February 20, 2026 Supreme Court ruling on International Emergency Economic Powers Act, April 2, 2026 proclamation under Section 232 with Q3 2026 effective date, and carve-outs for animal-health pharmaceutical products
- Added reference to 2025 Form 10-K instead of 2024 Form 10-K for Risk Factors
- Removed:
- Removed reference to aqua business divestiture from Business Overview
- Removed statement about 'consistently innovate to improve the health of animals' and 'fostering an inclusive, cause-driven culture'
- Removed mission statement 'Food and Companionship Enriching Life'
- Removed Bovaer product update (FDA approval May 2024, third quarter 2024 U.S. launch)
- Removed Experior product update (October 2024 FDA clearance approvals)
- Removed AdTab product update (April 2025 U.K. approval and launch)
- Removed statement about customers accelerating purchases of farm animal products internationally in Q2 2025 in anticipation of tariff increases
- Removed discussion of government incentives for sustainability products being frozen or rescinded
- Removed discussion of Bovaer adoption rate being tempered due to absence of government incentives
- Removed entire 'Sale of Future Revenue' section describing May 2025 Blackstone PSA agreement for XDEMVY royalties ($295 million)
- Reworded:
- Credelio Quattro update changed from 'Regulatory submissions have now been made' to 'Additional submissions have been made' and added December 2025 conditional approval for New World screwworm and April 2026 Australia launch and Canada approval
- Zenrelia update changed from 'received approval for Zenrelia in' to 'commercialized Zenrelia in'
- Product Development section changed from 'develop with partners or that we obtain' to 'with partners or obtain'
- Trade Environment section substantially reframed from discussing 2025 tariff impacts to discussing 2026 tariff developments and Supreme Court ruling
- Notes:
- The newer filing text appears truncated at the end of the Trade Environment section; full comparison of that section may not be complete
- The older filing text also appears truncated in the 'Sale of Future Revenue' section; the complete removal of this section cannot be fully verified from the provided text
Risk Factors
- Added:
- Added bullet point: 'an increased use of alternative distribution channels or changes within existing distribution channels' (filed 2026-05-06)
- Added reference to '2025 Form 10-K' instead of '2024 Form 10-K' (filed 2026-05-06)
- Removed:
- Removed bullet point: 'the impact of increased or decreased sales into our distribution channels resulting in fluctuations in our revenues' (was in filed 2025-11-05)
- Reworded:
- Changed 'inability to achieve goals or meet expectations of stakeholders' to 'inability to achieve our aspirations or meet the expectations of stakeholders' in the final ESG-related risk factor (filed 2026-05-06)
- Notes:
- The comparison is limited to the Forward-Looking Statements and Risk Factor Summary section; the actual detailed Risk Factors section (Item 1A) text was not provided in either filing excerpt
- Page number changes in the table of contents reflect different document lengths but do not indicate substantive Risk Factors section changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days2 buys ($199781) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-05-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ELAN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ELAN from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ELAN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 118,552,692
- Reported value $2,836,965,937
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ELAN had 36,003,865 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ELAN had 7.21% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.31 days to cover at the same settlement.
- Reported short interest (shares) 36,003,865
- Short interest (% of shares outstanding) 7.21%
- Prior settlement (shares) 35,819,082
- Reported change 0.52%
- Days to cover (reported) 7.31
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Zoetis (ZTS)
- Merck Animal Health (MRK)
- Boehringer Ingelheim Animal Health
- Idexx Laboratories (IDXX)
- Ceva Santé Animale
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELAN vs…
Frequently asked questions
What does Elanco (ELAN) do?
Elanco is a global animal health company that develops, manufactures, and markets products for the prevention and treatment of disease in both pets and farm animals. Its portfolio includes a broad range of veterinary pharmaceuticals, vaccines, and animal health additives aimed at improving animal well-being and productivity. The company operates across global markets, focusing on both companion animal health and farm animal health segments.
What sector is Elanco (ELAN) in?
Elanco (ELAN) is classified in the Health Care sector. Its industry is Animal Health. It trades on NYSE.
Who are Elanco's (ELAN) competitors?
Notable peers of Elanco (ELAN) include Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Idexx Laboratories and Ceva Santé Animale. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ELAN?
Yes — we hold 1 matched STOCK Act disclosure for ELAN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Elanco (ELAN) overbought or oversold right now?
Elanco (ELAN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELAN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.